PROCEPT BioRobotics (PRCT)
Market Price (6/7/2026): $27.35 | Market Cap: $1.5 BilSector: Health Care | Industry: Life Sciences Tools & Services
PROCEPT BioRobotics (PRCT)
Market Price (6/7/2026): $27.35Market Cap: $1.5 BilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -11% Megatrend and thematic driversMegatrends include Automation & Robotics. Themes include Surgical Robotics, Advanced Medical Devices, and Minimally Invasive Surgery. | Weak multi-year price returns2Y Excs Rtn is -98%, 3Y Excs Rtn is -93% Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 12% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -109 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -34% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 16% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -22%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -25% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11% Key risksPRCT key risks include [1] a history of unprofitability, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -11% |
| Megatrend and thematic driversMegatrends include Automation & Robotics. Themes include Surgical Robotics, Advanced Medical Devices, and Minimally Invasive Surgery. |
| Weak multi-year price returns2Y Excs Rtn is -98%, 3Y Excs Rtn is -93% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 12% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -109 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -34% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 16% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -22%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -25% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11% |
| Key risksPRCT key risks include [1] a history of unprofitability, Show more. |
Qualitative Assessment
AI Analysis | Feedback
PROCEPT BioRobotics (PRCT) stock has gained about 25% since 2/28/2026 because of the following key factors:
1. PROCEPT BioRobotics reported strong financial results for fiscal Q1 2026, exceeding revenue expectations and reaffirming robust full-year guidance. The company announced fiscal Q1 2026 revenue of $83.1 million, a 20% increase year-over-year, surpassing the consensus estimate of $80.52 million. U.S. procedures utilizing the Aquablation therapy grew approximately 30% year-over-year to 12,200. Management also reiterated its full-year 2026 revenue guidance, projecting between $390 million and $410 million, representing a 27% to 33% growth compared to 2025. Gross margin for the quarter improved to 65%.
2. The company achieved significant regulatory milestones and received strong clinical endorsements for its Aquablation therapy. PROCEPT BioRobotics obtained FDA clearance for its second-generation FirstAssist AI software, designed to enhance the Hydros system's image-guided planning capabilities. Additionally, the European Association of Urology (EAU) updated its clinical guidelines to issue a strong recommendation for Aquablation therapy for the surgical treatment of benign prostatic hyperplasia (BPH) with moderate to severe lower urinary tract symptoms. The AUA Guidelines also strengthened recommendations for Aquablation therapy.
Show more
Stock Movement Drivers
Fundamental Drivers
The 22.7% change in PRCT stock from 2/28/2026 to 6/6/2026 was primarily driven by a 18.2% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 6062026 | Change |
|---|---|---|---|
| Stock Price ($) | 22.69 | 27.83 | 22.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 308 | 322 | 4.5% |
| P/S Multiple | 4.1 | 4.9 | 18.2% |
| Shares Outstanding (Mil) | 56 | 57 | -0.8% |
| Cumulative Contribution | 22.7% |
Market Drivers
2/28/2026 to 6/6/2026| Return | Correlation | |
|---|---|---|
| PRCT | 22.7% | |
| Market (SPY) | 7.8% | 16.5% |
| Sector (XLV) | -4.1% | 32.6% |
Fundamental Drivers
The -12.2% change in PRCT stock from 11/30/2025 to 6/6/2026 was primarily driven by a -17.0% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 6062026 | Change |
|---|---|---|---|
| Stock Price ($) | 31.68 | 27.83 | -12.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 300 | 322 | 7.4% |
| P/S Multiple | 5.9 | 4.9 | -17.0% |
| Shares Outstanding (Mil) | 56 | 57 | -1.4% |
| Cumulative Contribution | -12.2% |
Market Drivers
11/30/2025 to 6/6/2026| Return | Correlation | |
|---|---|---|
| PRCT | -12.2% | |
| Market (SPY) | 8.5% | 22.0% |
| Sector (XLV) | -2.1% | 21.4% |
Fundamental Drivers
The -52.0% change in PRCT stock from 5/31/2025 to 6/6/2026 was primarily driven by a -61.8% change in the company's P/S Multiple.| (LTM values as of) | 5312025 | 6062026 | Change |
|---|---|---|---|
| Stock Price ($) | 58.00 | 27.83 | -52.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 249 | 322 | 29.3% |
| P/S Multiple | 12.8 | 4.9 | -61.8% |
| Shares Outstanding (Mil) | 55 | 57 | -2.8% |
| Cumulative Contribution | -52.0% |
Market Drivers
5/31/2025 to 6/6/2026| Return | Correlation | |
|---|---|---|
| PRCT | -52.0% | |
| Market (SPY) | 26.6% | 21.2% |
| Sector (XLV) | 17.4% | 28.0% |
Fundamental Drivers
The -16.8% change in PRCT stock from 5/31/2023 to 6/6/2026 was primarily driven by a -72.4% change in the company's P/S Multiple.| (LTM values as of) | 5312023 | 6062026 | Change |
|---|---|---|---|
| Stock Price ($) | 33.45 | 27.83 | -16.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 85 | 322 | 277.9% |
| P/S Multiple | 17.7 | 4.9 | -72.4% |
| Shares Outstanding (Mil) | 45 | 57 | -20.3% |
| Cumulative Contribution | -16.8% |
Market Drivers
5/31/2023 to 6/6/2026| Return | Correlation | |
|---|---|---|
| PRCT | -16.8% | |
| Market (SPY) | 83.4% | 29.5% |
| Sector (XLV) | 25.8% | 28.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PRCT Return | -40% | 66% | 1% | 92% | -61% | -14% | -36% |
| Peers Return | 6% | -14% | 17% | 21% | 1% | -19% | 6% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 11% | 102% |
Monthly Win Rates [3] | |||||||
| PRCT Win Rate | 25% | 67% | 42% | 83% | 8% | 50% | |
| Peers Win Rate | 48% | 48% | 53% | 62% | 53% | 30% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 67% | |
Max Drawdowns [4] | |||||||
| PRCT Max Drawdown | - | -34% | -40% | -21% | -69% | -37% | |
| Peers Max Drawdown | -22% | -37% | -22% | -15% | -23% | -32% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ISRG, MDT, BSX, TFX, SYK.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/5/2026 (YTD)
How Low Can It Go
| Event | PRCT | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -13.6% | -7.8% |
| % Gain to Breakeven | 15.8% | 8.5% |
| Time to Breakeven | 14 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -31.0% | -9.5% |
| % Gain to Breakeven | 44.8% | 10.5% |
| Time to Breakeven | 30 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -27.6% | -6.7% |
| % Gain to Breakeven | 38.1% | 7.1% |
| Time to Breakeven | 18 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -33.4% | -24.5% |
| % Gain to Breakeven | 50.1% | 32.4% |
| Time to Breakeven | 33 days | 427 days |
In The Past
PROCEPT BioRobotics's stock fell -13.6% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 15.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | PRCT | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -31.0% | -9.5% |
| % Gain to Breakeven | 44.8% | 10.5% |
| Time to Breakeven | 30 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -27.6% | -6.7% |
| % Gain to Breakeven | 38.1% | 7.1% |
| Time to Breakeven | 18 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -33.4% | -24.5% |
| % Gain to Breakeven | 50.1% | 32.4% |
| Time to Breakeven | 33 days | 427 days |
In The Past
PROCEPT BioRobotics's stock fell -13.6% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 15.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About PROCEPT BioRobotics (PRCT)
AI Analysis | Feedback
- AquaBeam Robotic System: An image-guided, surgical robotic system for minimally-invasive urologic surgery, focused on treating benign prostatic hyperplasia (BPH).
- Aquablation therapy: A minimally-invasive procedure for males suffering from lower urinary tract symptoms due to BPH, performed using the AquaBeam Robotic System.
AI Analysis | Feedback
PROCEPT BioRobotics (PRCT) primarily sells its AquaBeam Robotic System to other companies and institutions within the healthcare sector.
Its major customers are:
- Hospitals: Medical institutions that perform a wide range of surgical procedures, including urologic surgeries for conditions like benign prostatic hyperplasia (BPH).
- Surgical Centers / Urology Clinics: Specialized healthcare facilities or clinics focusing on urological treatments and procedures, which would acquire the AquaBeam Robotic System for their surgical offerings.
The provided information does not list the names of specific customer companies (hospitals or surgical centers) that have purchased the AquaBeam Robotic System, nor does it indicate if any of these are publicly traded entities with associated symbols.
AI Analysis | Feedback
null
AI Analysis | Feedback
Larry L. Wood, President & Chief Executive Officer Mr. Wood has served as President and Chief Executive Officer of PROCEPT BioRobotics since September 2, 2025, and as a member of its board of directors since April 2024. He brings over 40 years of experience in the medical technology industry, having held significant roles at Edwards Lifesciences and Baxter Healthcare Corporation. Most recently, at Edwards Lifesciences, he served as Corporate Vice President, Transcatheter Aortic Valve Replacement from February 2007 to September 2025, and as Group President for Surgical Structural Heart from 2023 to September 2025. Mr. Wood earned an MBA from Pepperdine Graziadio Business School. Kevin Waters, Executive VP, Chief Financial Officer Mr. Waters serves as the Executive Vice President and Chief Financial Officer of PROCEPT BioRobotics. He has a track record of financial leadership at publicly traded medical device companies, including Conceptus, Laserscope, and VISX, all of which were acquired by strategic buyers, generating approximately $3 billion in shareholder value. Before joining PROCEPT BioRobotics, Mr. Waters was Chief Financial Officer of Accuray, Inc. from September 2015 to October 2018. He began his career at PricewaterhouseCoopers, LLP, and holds a B.S. in Business Administration with concentrations in Accounting and Finance from Cal Poly San Luis Obispo. Alaleh Nouri, Executive VP, Chief Legal Officer Ms. Nouri has served as PROCEPT BioRobotics' Executive Vice President, Chief Legal Officer & Corporate Secretary since January 2022, and as Chief Compliance Officer since September 2018. She was previously the Senior Vice President, General Counsel & Corporate Secretary from July 2018 until December 2021. Prior to PROCEPT BioRobotics, Ms. Nouri was Senior Vice President, General Counsel, Corporate Secretary, and Chief Compliance Officer at Accuray Inc., a radiation oncology company, from February 2014 to July 2018. Her legal career spans over 15 years, encompassing private practice and in-house counsel roles where she advised on corporate, transactional, and regulatory compliance matters. Ms. Nouri earned her J.D. from U.C. College of the Law, San Francisco. Hisham Shiblaq, Executive Vice President and Chief Commercial Officer Mr. Shiblaq holds the position of Executive Vice President and Chief Commercial Officer at PROCEPT BioRobotics. Chris Christoforou, Executive VP, Operations Mr. Christoforou joined PROCEPT BioRobotics in April 2025 as Executive Vice President, Operations. Before this, he held various leadership roles at Nevro from 2016 through April 2025, including Chief Operating Officer and Senior Vice President of Technical Operations.AI Analysis | Feedback
Key Risks to PROCEPT BioRobotics (PRCT)
- Market Acceptance, Adoption, and Competition: PROCEPT BioRobotics operates with a relatively small install base for its AquaBeam Robotic System and Aquablation therapy, focusing on benign prostatic hyperplasia (BPH). A key risk involves the challenge of achieving broader market acceptance and adoption of this novel technology among urologists and hospitals, competing against long-established BPH treatments and other existing or emerging surgical technologies.
- Reimbursement Challenges: For a new medical device and therapy like the AquaBeam Robotic System and Aquablation therapy, securing and maintaining adequate and favorable reimbursement policies from government and private payers is crucial. Inadequate reimbursement can significantly hinder market penetration and financial viability.
- Intellectual Property Protection: As a surgical robotics company with proprietary technology, PROCEPT BioRobotics faces the ongoing risk of protecting its intellectual property, including patents related to the AquaBeam Robotic System and Aquablation therapy. Challenges to or loss of patent protection could diminish its competitive advantage.
AI Analysis | Feedback
The growing adoption and increasing clinical validation of less invasive, often office-based, non-robotic therapies for benign prostatic hyperplasia (BPH) could pose an emerging threat. These therapies, which require less hospital infrastructure and recovery time, may shift the standard of care for a significant portion of BPH patients away from more intensive, hospital-based robotic surgical procedures like Aquablation, thus limiting the market for PROCEPT BioRobotics' AquaBeam Robotic System.
AI Analysis | Feedback
PROCEPT BioRobotics (symbol: PRCT) focuses on developing transformative solutions in urology, primarily through its AquaBeam Robotic System and Aquablation therapy for benign prostatic hyperplasia (BPH).
The addressable market for PROCEPT BioRobotics' main product, Aquablation therapy, is estimated as follows:
- For the **U.S. market**, PROCEPT BioRobotics estimates an addressable market of approximately $30 billion for Aquablation therapy. Another company estimate for the total addressable market (TAM) for BPH surgery in the U.S. is $20 billion, corresponding to 8.2 million patients actively seeking treatment for BPH-related diseases.
- Globally, the aquablation therapy market is projected to be approximately $2.19 billion in 2026 and is expected to grow to approximately $7.05 billion by 2036.
AI Analysis | Feedback
PROCEPT BioRobotics (PRCT) anticipates several key drivers for future revenue growth over the next 2-3 years, stemming from its strategic focus on expanding its Aquablation therapy for benign prostatic hyperplasia (BPH) and exploring new market opportunities.
One primary driver is the acceleration of Aquablation procedure growth. The company is strategically shifting its operational focus to increasing procedure volume and gaining market share, aiming for U.S. procedure growth in the range of 39% to 48% in 2026. This is a critical component of their "next chapter" strategy to drive leadership in BPH treatment.
Another significant factor is the increase in the average selling price (ASP) of handpieces. PROCEPT BioRobotics has implemented a more disciplined pricing strategy by eliminating bulk purchase discounts, which resulted in a 5% sequential price increase in Q4 2025. Management expects the handpiece ASP to rise to approximately $3,500 in 2026, which is considered a meaningful tailwind for revenue growth.
The expansion of the installed base of AquaBeam and HYDROS Robotic Systems continues to be a crucial revenue driver. By the end of 2025, the company's U.S. installed base reached 718 systems, representing a 42% increase compared to the prior year. These system placements, particularly the HYDROS Robotic System, enable subsequent recurring revenue from handpiece sales as utilization grows.
International expansion also presents a notable growth opportunity. PROCEPT BioRobotics recently launched its HYDROS Robotic System in the United Kingdom and has plans for additional international expansion throughout 2026. This broadens the market for their Aquablation therapy beyond the U.S., where BPH impacts approximately 40 million men.
Finally, the company is exploring expansion into prostate cancer treatment as a longer-term growth avenue. Procedures in the WATER IV prostate cancer trial are anticipated to be completed by mid-2026, potentially opening up a new adjacent market for their robotic solutions.
AI Analysis | Feedback
Share Repurchases
PROCEPT BioRobotics has not reported any significant share repurchase programs or authorizations over the last 3-5 years.
Share Issuance
- PROCEPT BioRobotics completed its Initial Public Offering (IPO) on September 15, 2021, selling 6,556,000 shares of common stock at $25.00 per share, which generated total gross proceeds of $163.9 million.
- In October 2024, the company announced the pricing of an underwritten public offering of 1,923,076 shares of its common stock at $91.00 per share, expected to raise approximately $175 million in gross proceeds.
Inbound Investments
As a public company since September 2021, the primary significant inbound investment has been through its Initial Public Offering, which raised $163.9 million in gross proceeds.
Outbound Investments
There is no publicly available information indicating PROCEPT BioRobotics made any significant outbound investments, such as acquisitions or strategic investments in other companies, over the last 3-5 years.
Capital Expenditures
- PROCEPT BioRobotics's capital expenditures were $9.36 million for the fiscal year 2025.
- In the last 12 months (as of early 2026), capital expenditures amounted to $9.36 million.
- For the third quarter of 2025, the company invested $2.9 million in capital expenditures, primarily focused on long-term assets and infrastructure.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 105.75 |
| Mkt Cap | 88.4 |
| Rev LTM | 15,599 |
| Op Inc LTM | 3,664 |
| FCF LTM | 3,066 |
| FCF 3Y Avg | 2,125 |
| CFO LTM | 3,851 |
| CFO 3Y Avg | 3,072 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 19.4% |
| Rev Chg 3Y Avg | 13.3% |
| Rev Chg Q | 15.9% |
| QoQ Delta Rev Chg LTM | 3.6% |
| Op Inc Chg LTM | 11.7% |
| Op Inc Chg 3Y Avg | 10.1% |
| Op Mgn LTM | 19.3% |
| Op Mgn 3Y Avg | 18.5% |
| QoQ Delta Op Mgn LTM | -0.0% |
| CFO/Rev LTM | 20.8% |
| CFO/Rev 3Y Avg | 20.4% |
| FCF/Rev LTM | 15.6% |
| FCF/Rev 3Y Avg | 15.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 88.4 |
| P/S | 4.1 |
| P/Op Inc | 20.2 |
| P/EBIT | 19.9 |
| P/E | 21.5 |
| P/CFO | 17.4 |
| Total Yield | 3.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 2.5% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 1.4% |
| 3M Rtn | -11.7% |
| 6M Rtn | -20.3% |
| 12M Rtn | -21.9% |
| 3Y Rtn | 2.2% |
| 1M Excs Rtn | 4.6% |
| 3M Excs Rtn | -21.2% |
| 6M Excs Rtn | -25.2% |
| 12M Excs Rtn | -45.5% |
| 3Y Excs Rtn | -75.1% |
Price Behavior
| Market Price | $27.83 | |
| Market Cap ($ Bil) | 1.6 | |
| First Trading Date | 09/15/2021 | |
| Distance from 52W High | -56.7% | |
| 50 Days | 200 Days | |
| DMA Price | $25.50 | $30.68 |
| DMA Trend | down | indeterminate |
| Distance from DMA | 9.1% | -9.3% |
| 3M | 1YR | |
| Volatility | 68.6% | 59.9% |
| Downside Capture | 47.14 | 224.48 |
| Upside Capture | 81.70 | 66.26 |
| Correlation (SPY) | 20.5% | 23.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.04 | 1.83 | 0.94 | 1.36 | 1.15 | 1.19 |
| Up Beta | 0.42 | 2.79 | 0.59 | 1.00 | 1.25 | 1.02 |
| Down Beta | 1.66 | 1.17 | 0.84 | 0.46 | 0.44 | 1.10 |
| Up Capture | 38% | 74% | 123% | 145% | 52% | 133% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 11 | 21 | 32 | 57 | 109 | 352 |
| Down Capture | -225% | 206% | 103% | 193% | 165% | 110% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 9 | 20 | 31 | 67 | 139 | 395 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRCT | |
|---|---|---|---|---|
| PRCT | -54.0% | 60.1% | -1.07 | - |
| Sector ETF (XLV) | 16.9% | 15.0% | 0.83 | 27.9% |
| Equity (SPY) | 25.3% | 12.1% | 1.57 | 20.9% |
| Gold (GLD) | 27.6% | 26.9% | 0.88 | 7.8% |
| Commodities (DBC) | 36.9% | 19.0% | 1.52 | -1.1% |
| Real Estate (VNQ) | 12.5% | 13.3% | 0.63 | 22.9% |
| Bitcoin (BTCUSD) | -42.0% | 42.5% | -1.16 | 17.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRCT | |
|---|---|---|---|---|
| PRCT | -7.5% | 64.9% | 0.13 | - |
| Sector ETF (XLV) | 6.1% | 14.7% | 0.23 | 31.1% |
| Equity (SPY) | 13.5% | 17.1% | 0.62 | 33.6% |
| Gold (GLD) | 17.3% | 18.1% | 0.78 | 6.8% |
| Commodities (DBC) | 9.5% | 19.4% | 0.38 | 3.7% |
| Real Estate (VNQ) | 3.2% | 18.8% | 0.07 | 30.6% |
| Bitcoin (BTCUSD) | 11.3% | 54.6% | 0.40 | 20.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRCT | |
|---|---|---|---|---|
| PRCT | -3.8% | 64.9% | 0.13 | - |
| Sector ETF (XLV) | 9.9% | 16.6% | 0.48 | 31.1% |
| Equity (SPY) | 15.3% | 17.9% | 0.73 | 33.6% |
| Gold (GLD) | 13.0% | 16.0% | 0.67 | 6.8% |
| Commodities (DBC) | 7.1% | 18.0% | 0.32 | 3.7% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.24 | 30.6% |
| Bitcoin (BTCUSD) | 63.3% | 66.9% | 1.03 | 20.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/2/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/29/2026 | 10.7% | 14.2% | 21.3% |
| 2/25/2026 | -15.1% | -4.6% | -9.9% |
| 11/4/2025 | -9.7% | -10.5% | 2.4% |
| 8/6/2025 | -13.4% | -11.6% | -11.0% |
| 4/24/2025 | -5.6% | -3.1% | 3.6% |
| 2/25/2025 | 8.6% | 3.6% | -0.6% |
| 10/28/2024 | 32.3% | 34.2% | 42.2% |
| 8/1/2024 | -7.5% | -0.2% | 27.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 6 | 9 |
| # Negative | 10 | 11 | 8 |
| Median Positive | 8.6% | 9.7% | 21.3% |
| Median Negative | -8.4% | -7.3% | -10.6% |
| Max Positive | 32.3% | 34.2% | 49.7% |
| Max Negative | -25.3% | -18.5% | -26.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 04/30/2026 | 10-Q |
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/02/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 10/28/2024 | 10-Q |
| 06/30/2024 | 08/02/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 07/28/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/28/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
Recent Forward Guidance
Updated 6/1/2026Latest: Q1 2026 Earnings Reported 4/29/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 390.00 Mil | 400.00 Mil | 410.00 Mil | 0 | Affirmed | Guidance: 400.00 Mil for 2026 | |
| 2026 Revenue Growth | 27.0% | 30.0% | 33.0% | 0 | Affirmed | Guidance: 30.0% for 2026 | |
| 2026 U.S. Procedure Growth | 39.0% | 43.5% | 48.0% | 0 | Affirmed | Guidance: 43.5% for 2026 | |
| 2026 Gross Margin | 65.0% | 0 | Affirmed | Guidance: 65.0% for 2026 | |||
| 2026 Adjusted EBITDA | -30.00 Mil | -23.50 Mil | -17.00 Mil | 0 | Affirmed | Guidance: -23.50 Mil for 2026 | |
Prior: Q4 2025 Earnings Reported 2/25/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Total Procedures | 12,000 | 12,400 | 12,800 | ||||
| Q1 2026 Revenue | 79.00 Mil | 80.50 Mil | 82.00 Mil | ||||
| 2026 Revenue | 390.00 Mil | 400.00 Mil | 410.00 Mil | -4.8% | Lowered | Guidance: 420.00 Mil for 2026 | |
| 2026 Revenue Growth | 27.0% | 30.0% | 33.0% | ||||
| 2026 U.S. Procedure Growth | 39.0% | 43.5% | 48.0% | ||||
| 2026 Operating Margin | 65.0% | 1.2% | 0.8% | Raised | Guidance: 64.25% for 2025 | ||
| 2026 Operating Expenses | 350.00 Mil | 15.9% | Higher New | Actual: 302.00 Mil for 2025 | |||
| 2026 Adjusted EBITDA | -30.00 Mil | -23.50 Mil | -17.00 Mil | -32.9% | Raised | Actual: -35.00 Mil for 2025 | |
Insider Activity
Updated 4/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Nouri, Alaleh | EVP, CLO, CORP. SEC. | Direct | Sell | 3192026 | 25.96 | 5,363 | 139,231 | 2,735,133 | Form |
| 2 | Nouri, Alaleh | EVP, CLO, CORP. SEC. | Direct | Sell | 3182026 | 28.15 | 304 | 8,559 | 3,117,038 | Form |
| 3 | Waters, Kevin | EVP, CFO | Direct | Sell | 3182026 | 28.15 | 706 | 19,876 | 4,266,843 | Form |
| 4 | Nouri, Alaleh | EVP, CLO, CORP. SEC. | Direct | Sell | 3122026 | 25.65 | 3,243 | 83,197 | 2,848,178 | Form |
| 5 | Desai, Antal Rohit | Kestrel Fund, L.P. | Buy | 3092026 | 24.55 | 98,699 | 2,422,891 | 10,463,999 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.